Transcatheter atrioventricular (AV) junction ablation with radiofrequency energy was performed in five patients with AV nodal reentrant tachycardia. Disappearance of ventriculoa-trial condcution in all patients was showed and no dual pathway was observed in four patients, in whom three patients occurred first degree AV block after ablation. No tachycardia was showed in all patients in the electrophysiology test and in follow-up of 1. 5-12. 5 months. The results sug-gested that the application of radiofrequency energy may be a suitable and safe therapeutic mothed for modification of AV nodal conduction in patients with AV nodal reentrant tachycardia.

AIM: To determine the effect of intermittent hypoxia (IH) precondition on ischemic myocardium by using a rabbit model of chro nic myocardial ischemia with left anterior descending (LAD) banding. METHODS: Male, adult New Zealand white rabbits were assigned into three groups randomly. (1) normal group (N group), (2) control group (C group), (3) IH precondition group (H group). A LAD band was placed in C and H group firs t. The rabbits in H group were exposed to altitude of 5 000 m, for 6 h/day c ontin uously. According to IH precondition duration, the animals were subdivided into 7-days group (H1) and 42-days group (H2). After these experiments, the mRNA conc entrations of vascular endothelial growth factor (VEGF), hypoxia induced factor (HIF-1?), endothelial nitric oxide synthase (eNOS) and the expression of VEGF p rotein were detected. Tissue sections were stained for alkaline phosphatase with indoxyl-tetrazolium method to detect capillary density. RESULTS: The mRNA levels of VEGF, HIF-1?, eNOS and expression V E GF protein were increased in H group significantly. Compared with C and N group, the capillary density in H group was increased significantly. CONCLUSION: IH precondition increases angiogenesis in chronic is chemic myocardium in rabbits.

AIM: To investigate affection of the novel Ginko biloba extract GBE50 on bcl-2、bcl-xL gene expression in rabbit myocardium. METHODS: Adult male New Zealand rabbits were randomly divided into 2 groups. GBE50 group were orally administrated with 100 mg/kg GBE50 daily. Control group were only administrated vehicle 2% CMC-Na. After being raised for 4 weeks, the animals were killed and the ventricular tissue were excised. We performed reverse transcriptase polymerase (RT-PCR) to measure gene expression of bcl-2、bcl-xL. Semiquantitative analysis method based on gel electrophoresis image was adopted to compare gene expression among groups. RESULTS : The gene expression of bcl-2、bcl-xL significantly increased in GBE50 group compared with control group. CONCLUSION: The novel Ginko biloba extract GBE50 can promote expression of the antiapoptotic gene bcl-2、bcl-xL in rabbit myocardium.

Objective: To detect the expression of SVEP1, PKHD1 and P53 in primary liver cancer tissues by immunohistochemistry for predicting the recurrence of liver cancer. Methods: The clinical data of 103 patients with primary liver cancer who underwent surgical resection at Tianjin Medical University Cancer Institute and Hospital were gathered from January 2013 to January 2014 and analyzed retrospectively. Expression values of three different proteins were used to develop separate immunohistochemical scores for the prog-nosis of recurrence in patients. The patients were classified into either a high-risk or a low-risk group based on their immunohisto-chemical scores through ROC curve analysis. The difference in recurrence ratio between the two groups was then compared using the common research index of disease-free survival (DFS). Results: The median age of the total patients was 55 years (range 21-88 years), the median AFP level was 70.6 (range 1.03-718840.0) μg/L, the median CA19-9 level was 22.89 (range 0.6-1000.0) kU/L, and the medi-an tumor size was 4.5 (1.0-27.0) cm. The expression levels of SVEP1, PKHD1, and P53 in primary liver tumors were detected by immu-nohistochemistry and assigned separate immunohistochemical scores. The areas under the ROC curves of the immunohistochemical scores of SVEP1, PKHD1, and P53 were 0.861, 0.829, and 0.716, respectively. The critical values of SVEP1, PKHD1, and P53 were 4, 4, and 1 point, respectively (P<0.001). The three-year DFS rates among the SVEP1 high-risk (expression≤4 points) and low-risk groups (expression>4 points) were 4.1% and 51.7%, respectively. Similarly, the three-year survival rates among the PKHD1 high-risk (expres-sion≤4 points) and low-risk groups (expression>4 points) were 5.3% and 51.9%, respectively. The three-year DFS rates among the P53 high-risk (expression>1 point) and the low-risk group (expression≤1 point) were 6.3% and 27.3%, respectively. The survival differenc-es between all the pairs were statistically significant (P<0.001,<0.001, and 0.003 respectively). When PKHD1 was used in combination with SVEP1, the ROC curve had an area of 0.897 (P<0.001) with a sensitivity of 76.5% and a specificity of 94.4%. Conclusions: The accu-racy of P53 data for predicting primary liver cancer recurrence is insufficient and therefore it is not recommended for use. SVEP1 and PKHD1 data achieve sufficient accuracy for predicting the recurrence of primary liver cancer. Since SVEP1 data impart a higher specifici-ty and PKHD1 data impart a higher sensitivity to the prognosis scores, the combined use of the two markers is better than being used individually.

Objective:To study the expression level of programmed death ligand 1 (PD-L1) in combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and its correlation with the clinical characteristics and prognosis.Methods:The clinical data of 75 patients with cHCC-CCA undergoing surgery in Tianjin Medical University Cancer Institute and Hospital from January 2011 to December 2019, including 61 males and 14 females, with a median age of 55 years (36 to 77). Immunohistochemistry was conducted to determine the PD-L1 expression in tumor. The status of PD-L1 expression, clinicopathological data and prognosis of patients were analyzed.Results:In low-differentiated cHCC-CCA tissues, the proportion of PD-L1 expression (21.1%, 8/38) was higher than that in moderately to well-differentiated cHCC-CCA tissues (2.70%, 1/37, χ2=4.366, P=0.037). The median disease-free survival (DFS) and overall survival (OS)of PD-L1 positive patients were 12.3 and 15.1 months, respectively, lower than those of PD-L1 negative patients (14.4 and 23.3 months). The difference of DFS was statistically significant ( χ2=4.052, P=0.044). In multivariate analysis, major vascular invasion (DFS: HR=1.965, 95% CI: 1.119-3.450, P=0.019; OS: HR=1.781, 95% CI: 1.022-3.105, P=0.042) and lymph node metastasis (DFS: HR=2.451, 95% CI: 1.1033-5.814, P=0.042; OS: HR=2.652, 95% CI: 1.120-6.279, P=0.027) were identified as independent prognostic factors affecting DFS and OS. Conclusions:The proportion of PD-L1 positive is higher inthe low-differentiated cHCC-CCA tissue compared to that in moderately to well-differentiated cHCC-CCA. The major vascular invasion and lymph node metastasis are independent factors affecting the prognosis of patients with cHCC-CCA.